Pre-operative assessment of residual disease in locally advanced breast cancer patients: A sequential study by quantitative diffusion weighted MRI as a function of therapy
- 1 October 2017
- journal article
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 42, 88-94
Abstract
No abstract availableKeywords
Funding Information
- Anusandhan National Research Foundation (SP/SO/HS-80/2006, SR/SO/HS/213/2012)
This publication has 38 references indexed in Scilit:
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2012
- Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast CancerAnnals of Surgical Oncology, 2011
- Heterogeneity in breast cancerJournal of Clinical Investigation, 2011
- Primary Systemic Therapy of Breast CancerThe Oncologist, 2006
- Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast CancerThe Cancer Journal, 2006
- Primary systemic therapy in operable breast cancer: clinical data and biological fall-outAnnals of Oncology, 2006
- MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free SurvivalAmerican Journal of Roentgenology, 2005
- Prospective Comparison of Mammography, Sonography, and MRI in Patients Undergoing Neoadjuvant Chemotherapy for Palpable Breast CancerAmerican Journal of Roentgenology, 2005
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998